Arbutus Biopharma (ABUS) Depreciation & Amortization - Total (2013 - 2021)

Arbutus Biopharma has disclosed Depreciation & Amortization - Total across 9 years of filings, most recently posting $447000.0 for Q3 2021.

• Depreciation & Amortization - Total for Q3 2021 came in at $447000.0, down 8.78% year-over-year; the trailing twelve-month figure through Jun 2022 was $447000.0 (down 75.92% YoY), and the FY2020 annual result was $2.0 million, down 2.47% from the prior year.
• Depreciation & Amortization - Total came in at $447000.0 for Q3 2021 at Arbutus Biopharma, up from $436000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization - Total ranged from a high of $620000.0 in Q4 2017 to a low of $334000.0 in Q1 2017.
• The 5-year median for Depreciation & Amortization - Total is $501000.0 (2020), against an average of $502105.3.
• Across the five-year window, Depreciation & Amortization - Total surged 103.78% in 2017 and declined 18.71% in 2018, its largest moves.
• Arbutus Biopharma's Depreciation & Amortization - Total stood at $620000.0 in 2017, then declined by 18.71% to $504000.0 in 2018, then grew by 0.6% to $507000.0 in 2019, then dropped by 3.94% to $487000.0 in 2020, then declined by 8.21% to $447000.0 in 2021.
• The last three Depreciation & Amortization - Total figures came in at $447000.0 (Q3 2021), $436000.0 (Q2 2021), and $443000.0 (Q1 2021), per Business Quant data.